Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | GAA | P10253 | 4/20 | 0.57 |
| ▸ | GLA | P06280 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4898553 | 0.78 | KDM4E (0.60) | KDM4EGAAGLAMAPTHSD17B2 | |
| SCHEMBL4734537 | 0.73 | KDM4E (0.68) | KDM4EGAAGLAMAPTCA12 | |
| SCHEMBL10464803 | 0.73 | KDM4E (1.00) | KDM4EGAAGLAMAPTCA12 | |
| SCHEMBL4898591 | 0.73 | KDM4E (0.54) | KDM4EGAAGLAMAPTHSD17B2 | |
| SCHEMBL31032981 | 0.71 | KDM4E (0.66) | KDM4EGAAGLAMAPTCA12 | |
| SCHEMBL3056728 | 0.71 | KDM4E (0.60) | KDM4EGAAGLAHSD17B2 | |
| SCHEMBL10749314 | 0.69 | KDM4E (0.62) | KDM4EGAAGLAMAPTHSD17B2 | |
| SCHEMBL9341344 | 0.69 | KDM4E (0.57) | KDM4EGAAGLAMAPTCA12 | |
| SCHEMBL4904432 | 0.69 | KDM4E (0.57) | KDM4EGAAGLAMAPTHSD17B2 | |
| SCHEMBL1857268 | 0.68 | CHEK1 (0.48) | KDM4EGAAGLAMAPTCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952364-B2 | TRK inhibitors useful as anticancer drugs | TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED (CN) | 2024-04-09 | — | — | US | disclosed |
| CN-112739691-B | TRK inhibitors as anticancer agents | 泰励生物科技（上海）有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20220388983-A1 | TRK INHIBITORS USEFUL AS ANTICANCER DRUGS | TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED (CN) | 2022-12-08 | — | — | US | disclosed |
| EP-3848365-A1 | TRK INHIBITOR AS ANTI-CANCER DRUG | Tyligand Bioscience (Shanghai) Limited (CN) | 2021-07-14 | — | — | EP | disclosed |
| CN-112739691-A | TRK inhibitors as anticancer agents | 泰励生物科技（上海）有限公司 | 2021-04-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952364-B2 | TRK inhibitors useful as anticancer drugs | NTRK1, NTRK3, MUSK | KDM4E 2651/4885GAA 3942/4885GLA 3617/4885 |
| US-20220388983-A1 | TRK INHIBITORS USEFUL AS ANTICANCER DRUGS | NTRK1, NTRK3, MUSK | KDM4E 2651/4885GAA 3942/4885GLA 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.